Login to Your Account



Genmab Shares Rise on Ofatumumab CLL Data

By Cormac Sheridan


Wednesday, December 10, 2008
Shares in Genmab A/S gained as much as 13 percent during trading Tuesday following the release of additional clinical data on Arzerra (ofatumumab), an anti-CD20 monoclonal antibody undergoing a Phase III trial in patients with refractory chronic lymphocytic leukemia (CLL). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription